Emilia Welch, PharmD, MBA

Comorbidities and cognitive impairment worsen non-adherence to anti-seizure medications in older adults.

Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.

Axicabtagene ciloleucel (Yescarta) was the first CAR T-cell immunotherapy to be approved for relapsed or refractory large B-cell lymphoma.